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Toll-like receptors (TLRs) are critical in mediating
innate immune responses against infections. How-
ever, uncontrolled TLR-triggered inflammation is
associated with endotoxin shock. To better under-
stand the homeostatic mechanisms induced by
TLR4 signaling, we screened a group of key cyto-
kines, chemokines, growth factors, and their recep-
tors for bacteria- or LPS-induced expression. The
surface vascular endothelial growth factor recep-
tor-3 (VEGFR-3) and its ligand VEGF-C were upregu-
lated in macrophages. VEGFR-3 ligation by VEGF-C
significantly attenuated proinflammatory cytokine
production. Notably, ablation of the ligand-binding
domain or tyrosine kinase activity of VEGFR-3
rendered mice more sensitive to septic shock.
VEGFR-3 restrained TLR4-NF-kB activation by regu-
lating the PI3-kinase-Akt signaling pathway and
SOCS1 expression. Aside from targeting lymphatic
vessels, we suggest a key role of VEGFR-3 onmacro-
phages to prevent infections that is complicated with
lymphoedema. Thus, VEGFR-3-VEGF-C signaling
represents a ‘‘self-control’’ mechanism during anti-
bacterial innate immunity.
INTRODUCTION
Toll-like receptors (TLRs) recognize pathogen-associated
molecular patterns (PAMPs) and activate transcription factors
to produce various proinflammatory cytokines and clear
invading pathogens (Akira and Takeda, 2004). However, exces-
sive inflammatory responses initiated by TLRs can disrupt im-
mune homeostasis and result in immunopathological conditions
such as sepsis (or septic shock) (Kondo et al., 2012). Sepsis
is the systemic inflammatory response to infection and has ahigh rate of mortality. TLRs play critical roles in the development
of sepsis in response to both exogenous pathogens and endog-
enous ligands. The endotoxin lipopolysaccharide (LPS) from
Gram-negative bacteria, and bacterial RNA or DNA is known to
be potent stimuli of inflammatory responses via TLR4, TLR3,
and TLR9, respectively. Previous studies have demonstrated
that increased TLR4 expression is correlated with mortality in
the CLP (cecal ligation and puncture)-induced mouse sepsis
model (Williams et al., 2003), whereas downregulation of surface
TLR4 could induce endotoxin tolerance (Nomura et al., 2000).
Furthermore, the TLR4 antagonist E5564 (eritoran tetrasodium)
has been used in a phase II trial that aims to decrease mortality
in sepsis patients (Tidswell et al., 2010). Although past efforts
have identified multiple intracellular regulators to inhibit TLR-
signaling (Kondo et al., 2012; Liew et al., 2005), only few surface
receptors were demonstrated to reduce mortality in response to
endotoxin shock. Nevertheless, although multiple inflammatory
cytokines have been suggested as possible biomarkers of
sepsis (Pierrakos and Vincent, 2010), the molecular mechanisms
that regulate septic shock are poorly understood.
Previous findings have suggested that many negative effec-
tors are induced by inflammatory stimuli, which then function
as feedback loops to dampen inflammation or induce endotoxin
tolerance. To identify cytokine-receptor pairs that limit TLR-trig-
gered inflammation, we examined the expression of an array of
cytokines, chemokines, growth factors, and their surface recep-
tors in primary macrophages challenged with Gram-negative
bacteria and TLR stimuli. We found that vascular endothelial
growth factor receptor-3 (VEGFR-3) and its ligand, VEGF-C,
were substantially increased by the TLR agonists. Previous
studies have elucidated that VEGFR-1 and VEGFR-2 on vascular
endothelial cells mediate angiogenesis, whereas VEGFR-3 (also
termed Flt-4) on lymphatic endothelial cells regulates lymphan-
giogenesis (Adams and Alitalo, 2007; Lohela et al., 2009). Inter-
estingly, enhanced circulating concentrations of VEGF-A (also
termed VEGF) and its binding with VEGFR-1 have been linked
with severe sepsis in humans and mice (van der Flier et al.,
2005; Yano et al., 2006). By contrast, another VEGF family mem-
ber PIGF, which binds VEGFR-2, could not exacerbate the toxicImmunity 40, 501–514, April 17, 2014 ª2014 Elsevier Inc. 501
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VEGFR-3 Limits TLR4-Triggered Inflammatory Responseeffects of LPS (Yano et al., 2006). It is still unknown how VEGFR-
3-VEGF-C regulates TLR-triggered inflammation and sepsis.
In this study, we demonstrated that serum VEGF-C (but not
VEGF-D) expression was significantly increased in patients and
in mouse models of septic shock, suggesting a new possible
diagnostic biomarker for sepsis. Unlike other intracellular nega-
tive molecules (Liew et al., 2005), the enhanced surface
VEGFR-3 could be ligated by VEGF-C to reduce TLR4-triggered
production of proinflammatory cytokines in macrophages. Loss
of the ligand-binding-domain or the tyrosine kinase activity of
VEGFR-3 resulted in greater mortality of the mice in response
to endotoxin shock induction. Upon VEGF-C ligation, VEGFR-3
bound p85a to activate the PI3 kinase-Akt pathway for TLR4
internalization and decreased NF-kB activation. Thus, VEGFR-
3 signaling represents a negative feedback mechanism by
immune cells to avoid ‘‘overreaction’’ during bacterial infection.
This suggests that VEGFR-3 ligation by VEGF-C might have
potential clinical applications to prevent septic shock or severe
infections.
RESULTS
LPS Treatment and Gram-Negative Bacterial Infection
Enhance VEGF-C and VEGFR-3 Expression in
Macrophages
Macrophages are one of the major sources of proinflammatory
cytokines involved in endotoxin shock or tolerance (Biswas
and Lopez-Collazo, 2009; Harrison, 2010). To identify cytokine-
receptor pairs involved in TLR-signaling and the induction of
endotoxin shock, we screened the expression of 43 cytokines,
chemokines, growth factors, and their receptors in macro-
phages after treatment with various TLR stimuli or Gram-nega-
tive bacteria, including Salmonella typhimurium (strain SL1344)
and Escherichia coli (E. coli). Consistent with previous studies
(Pierrakos and Vincent, 2010), quantitative RT-PCR assays
revealed substantial induction of multiple proinflammatory
cytokine and chemokine genes in macrophages, including
interleukin-6 (IL-6), IL-1b, CCL2, and CXCL10. However, the
expression of their receptors, including IL-6R, IL-1R, CCR2,
and CXCR3, were minimally affected or even reduced (see
Figure S1A available online). In contrast, growth factor VEGF-C
and its receptor VEGFR-3 were both elevated (Figure 1and Fig-
ure S1). LPS stimulation and E. coli infection rapidly induced
VEGF-C expression at the mRNA and protein levels in murine
peritoneal exudate macrophages (PEMs), bone-marrow-derived
macrophages (BMMs) (Figure 1A), and PMA-treated human
THP-1 cells (Figure S1B). This effect was observed as early as
when macrophages were stimulated for 15 min. In mice with
LPS-induced endotoxin shock, serum concentrations of VEGF-
C were increased greater than 10-fold compared with those in
PBS-treated mice. By contrast, serum VEGF-D was present at
a relatively low concentration even after mice developed septic
shock (Figure 1B). We also observed that serum VEGF-C was
greatly increased in SL1344-infected mice, whereas serum
VEGF-D was only slightly enhanced (Figure 1C). Importantly,
the physiological relevance of the elevated serum VEGF-C con-
centrations was confirmed in human sepsis patients (Figure 1D).
Unlike other receptors (Figure S1A), the mRNA or surface
expression of VEGFR-3 was considerably increased in murine502 Immunity 40, 501–514, April 17, 2014 ª2014 Elsevier Inc.PEMs after LPS- or E. coli-treatment (Figure 1E and 1F), as
well as in LPS-stimulated human THP-1 cells (Figure S1C).
Although VEGFR-3 colocalized with TLR4 in macrophages (Fig-
ure S1D), it did not bind to TLR4 in an immunoprecipitation assay
(Figure S1E). Together, we have shown that Gram-negative
bacterial infection or LPS stimulation significantly elevates the
expression of VEGFR-3 and VEGF-C in murine and human
macrophages, suggesting a possible diagnosis marker of serum
VEGF-C for septic shock.
TLR4-NF-kB Signaling Triggers VEGFR-3 Expression,
which Negatively Regulates Proinflammatory Cytokine
Production
Upon recognition of LPS or Gram-negative bacteria, TLR4 initi-
ates MyD88-dependent pathways for NF-kB activation, which
is linked to excessive inflammation and endotoxin shock (Akira
and Takeda, 2004; Kondo et al., 2012; Liew et al., 2005).
We therefore asked whether TLR4-MyD88-NF-kB signaling
induced the expression of VEGFR-3 and VEGF-C. The NF-kB in-
hibitor PDTC (pyrrolidine dithiocarbamate) profoundly blocked
VEGFR-3 expression in LPS-stimulated PEMs (Figure 2A).
Sequence analysis with the TSEARCH program (Heinemeyer
et al., 1998) predicted several potential NF-kB binding sites
in the promoter region of VEGFR-3 (Figure S2A). The occupation
of the VEGFR-3 promoter region by the NF-kB subunit p65 was
detected in LPS-stimulated PEMs using chromatin immunopre-
cipitation (ChIP) assays (Figure 2B). Knockdown of p65 indeed
reduced expression of VEGFR-3 and VEGF-C (Figure 2C).
Also, LPS-treated MyD88-deficient BMMs significantly reduced
the mRNA expression of VEGFR-3 and VEGF-C (Figure 2D).
Consistent with previous studies, knockdown of p65 or lack of
MyD88 failed to induce IL-6 expression (Figure S2BC).
We then questioned how VEGF-C ligation of VEGFR-3
affected TLR4-triggered proinflammatory cytokine production.
Macrophages were treated with LPS alone or together with
exogenous VEGF-C. Exogenous VEGF-C reduced LPS-induced
IL-6, IL-1b, and tumor necrosis factor alpha (TNF-a) expression
(Figure 2E). To further confirm the negative role of VEGFR-3
in TLR4-triggered inflammatory responses, we knocked down
VEGFR-3 expression by siRNA in primary macrophages (Fig-
ure S2D). In LPS-treated PEMs, knockdown of VEGFR-3
promoted expression of IL-6, IL-1b, and TNF-a (Figure 2F). In
agreement with this, VEGFR-3 overexpression profoundly
blocked expression of these proinflammatory cytokines in
LPS-stimulated human THP-1 cells (Figure 2G). Collectively,
TLR4-MyD88-NF-kB signaling upregulates VEGF-C and
VEGFR-3 expression, whereas VEGF-C ligation of VEGFR-3
forms a negative feedback loop to inhibit TLR4-induced inflam-
matory responses.
The VEGFR-3 Ligand-Binding Domain Protects against
LPS- or Gram-Negative Bacteria-Induced Septic Shock
As a surface tyrosine kinase receptor, VEGFR-3 has the basal
amount of autophosphorylation, and VEGF-C binding further en-
hances its tyrosine phosphorylation (Kukk et al., 1996; Olsson
et al., 2006). VEGFR-3 lacking the extracellular ligand-binding
domain (LBD, i.e., immunoglobulin [Ig]-like domains 2 and 3) fails
to interact with VEGF-C (Zhang et al., 2010). Because VEGF-C
and VEGFR-3 null mice are embryonic lethal (Dumont et al.,
Figure 1. LPS Treatment and Gram-Negative Bacterial Infection Enhance VEGF-C and VEGFR-3 Expression in Macrophages
(A) The mRNA or protein expression of VEGF-C from the mock, LPS-stimulated (1 mg/ml) or E. coli-infected murine BMMs or PEMs.
(B and C) Serum concentrations of VEGF-C or VEGF-D in the PBS-treated, LPS-shock (48 hr) or SL1344-infected mice (Day 6).
(D) Serum VEGF-C concentrations from human healthy controls or patients with sepsis (n = 20 or 24).
(E and F) The mRNA or surface expression of VEGFR-3 in the mock, LPS-stimulated or E. coli-infected PEMs.
Error bars represent mean ± SEM, representative of at least three experiments. *p% 0.05, **p% 0.01. See also Figure S1.
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VEGFR-3 Limits TLR4-Triggered Inflammatory Response1998; Karkkainen et al., 2004), we used Vegfr3-LBDFlox/WT and
Vegfr3WT/DLBD; Lysozyme M (LysM)-Cre+/+ mice to generate
mouse models expressing the homozygous Vegfr3DLBD/DLBD
specifically in myeloid cells (named as Vegfr3DLBD/DLBD). This
mouse model allowed us to examine whether the ligand-medi-
ated VEGFR-3 signaling in macrophages was essential for the
inhibition of inflammation. LPS-stimulated Vegfr3DLBD/DLBD
macrophages indeed significantly increased IL-6, IL-1b, and
TNF-a expression comparedwith thewild-type (WT) and the het-
erozygous Vegfr3WT/DLBD macrophages (Figure 3A). In agree-ment with the higher expression of VEGFR-3 at 12 hr than those
at 6 hr (Figure 1E), the relative enhancement in the expression
of these proinflammatory cytokines became greater when
Vegfr3DLBD/DLBD macrophages were stimulated with LPS for
longer periods (i.e., <20% enhancement at 6 hr versus R50%
enhancement at 12 hr; data not shown).
Next, we tested whether the Vegfr3DLBD/DLBD mice were sen-
sitive to LPS-induced endotoxin shock. These mutant animals
did not show any obvious abnormalities in the frequency of
B220+, CD3+, CD4+, or CD8+ cells when bred in an SPF facilityImmunity 40, 501–514, April 17, 2014 ª2014 Elsevier Inc. 503
Figure 2. TLR4-NF-kB Signaling Triggers VEGFR-3 Expression, which Negatively Regulates Proinflammatory Cytokine Production
(A) The mRNA expression of VEGFR-3 in the mock or LPS-stimulated PEMs after treatment with DMSO or the NF-kB inhibitor PDTC.
(B) The relative amount of VEGFR-3 DNA binding to p65 by ChIP assay.
(C) The VEGFR-3 mRNA expression or VEGF-C concentrations in the control siRNA or sip65 transfected PEMs.
(D) The mRNA expression of VEGFR-3 or VEGF-C in the mock or LPS-activated Myd88+/+ and Myd88/ BMMs.
(legend continued on next page)
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VEGFR-3 Limits TLR4-Triggered Inflammatory Response(Figure S3A). Their bone marrow also showed comparable effi-
ciency at M-CSF-induced BMM generation in vitro (Figure S3B).
In response to LPS-induced septic shock, the Vegfr3DLBD/DLBD
mice displayed heightened sensitivity (median survival time =
32 hr) compared with the WT control or heterozygous mice
(Figure 3B). This was associated with more severe lung injury
in the Vegfr3DLBD/DLBD mice with more immune cell infiltration
(Figure 3C). In agreement with this, the Vegfr3DLBD/DLBD macro-
phages enhanced LPS-triggered production of chemokines
CCL2 and CXCL10 (Figure 3D).
To confirm this phenotype under pathogen-induced endo-
toxin shock, we used SL1344 to induce sepsis in the WT, het-
erozygous or Vegfr3DLBD/DLBD mice. The Vegfr3DLBD/DLBD
mice died earlier with lower survival rates (Figure 3E), which
displayed prominent lung injury (Figure 3F). In agreement
with this, SL1344-infected Vegfr3DLBD/DLBD macrophages
markedly increased the production of IL-6, IL-1b, TNF-a,
CCL2, and CXCL10 (Figure S3C) without affecting CCL3 or
CCL5 (Figure S3D). Next, we tested whether WT Vegfr3 could
rescue the phenotype caused by the mutant Vegfr3DLBD.
WT Vegfr3 was overexpressed in RAW264.7 cells that
stably expressed Vegfr3DLBD; and this partially reversed
Vegfr3DLBD-triggered excessive production of IL-6 and
CXCL10 (Figure S3E).
Interestingly, we observed that the anti-inflammatory cytokine
IL-10 was increased in macrophages after exogenous VEGF-C
treatment alone or together with LPS (Figure S3F). Consis-
tent with the uncontrolled inflammatory responses in the
Vegfr3DLBD/DLBD mice, the mRNA expression of IL-10 was
decreased in LPS-stimulated Vegfr3DLBD/DLBD macrophages
(Figure 3G). The serine/threonine kinase GSK3b (glycogen syn-
thase kinase 3b) was reported to negatively regulate LPS-
induced production of IL-10 (Martin et al., 2005). When the
Vegfr3DLBD/DLBD macrophages were treated with the GSK3
inhibitor SB216763, IL-10 was potently increased to the same
amount as that in the WT or Vegfr3WT/DLBD cells (Figure 3G).
While phosphorylation at serine 9 reduces GSK3b activity,
we observed that the p-GSK3b (Ser9) amount was decreased
in LPS-stimulated Vegfr3DLBD/DLBD macrophages (Figure 3H).
This suggests that GSK3b might be one of the downstream
effectors of VEGFR-3 in response to LPS stimulation or
Gram-negative bacterial infection.
The Tyrosine Kinase Activity of VEGFR-3 Is Critical for
Inhibition of Septic Shock
One of the key functions of VEGF-C ligation is to increase
VEGFR-3 phosphorylation and kinase activity (Olsson et al.,
2006). A Chy mouse carries the point mutation I1053F (also
termed Vegfr3TKmut) in the conserved cytoplasmic tyrosine
kinase domain, which impairs VEGFR-3 kinase activity (Karkkai-
nen et al., 2001; Zhang et al., 2010); this mouse model develops
similar lymphoedema phenotype as human lymphoedema pa-
tients. The inherited FLT4 (i.e., Vegfr3) missense mutations
with reduced kinase activity have been identified in lymphoe-(E–G) IL-6 concentrations or the mRNA expression of IL-6, IL-1b, and TNF-a wer
presence of exogenous VEGF-C, (F) the mock or siVEGFR-3-transfected PEMs
control vector.
Error bars represent mean ± SEM, representative of at least three experiments,dema patients (Karkkainen et al., 2000). Interestingly, these
patients are further complicated by infections (Karkkainen and
Petrova, 2000). We therefore asked whether Vegfr3TKmut
affected macrophage function to cause infections, aside from
affecting vascular or lymphatic endothelial cells to result in
lymphoedema.
Because the homozygous Vegfr3TKmut/TKmut genotype is
embryonic lethal, we compared macrophages between the
Vegfr3WT/TKmut mice and WT mice. The Vegfr3WT/TKmut mice
showed normal percentages of B cells and CD3+, CD4+, CD8+
T cells (Figure S4B). Although the Vegfr3WT/TKmut mice were
on C3H background, we confirmed no Tlr4 missense muta-
tion (Pro/His) in these mice (Figure S4C) (Poltorak et al.,
1998). Compared with the SL1344-infected WT mice, the
Vegfr3WT/TKmut mice had reduced survival rates with more body
weight loss (Figure 4A) and displayed more severe lung injury
(Figure 4B). The in vivo production of IL-6, IL-1b, and TNF-a
was enhanced (Figure 4C), whereas IL-10 expression was
reduced (Figure 4D) in the SL1344-infected Vegfr3WT/TKmut
mice. In agreement with this, LPS-treated Vegfr3WT/TKmut macro-
phages significantly increased IL-6 secretion, but reduced the
mRNA expression of IL-10 (Figure S4D). We next stably overex-
pressedWT Vegfr3 and Vegfr3TKmut into RAW264.7 cells (termed
RAW-R3WT or RAW-R3TKmut). Comparedwith RAW-R3WT, RAW-
R3TKmut secreted higher amounts of IL-6 and IL-1b after LPS
stimulation (Figure S4E). These observations indicate that
VEGFR-3 is dependent on its tyrosine kinase activity to limit
TLR-triggered inflammatory responses and protect the host
from septic shock.
VEGFR-3 Suppresses TLR4-Triggered NF-kB Activation
Because TLR4-triggered NF-kB activation leads to the produc-
tion of IL-1b, IL-6, TNF-a, CCL2, and CXCL10 (West et al.,
2006), we next asked whether VEGFR-3 affected NF-kB activa-
tion to reduce the production of these cytokines or chemokines.
Knockdown of VEGFR-3 enhanced p65 nuclear translocation af-
ter LPS treatment for 15 or 30 min (Figure 5A). Previous studies
demonstrated that IKK (IkB kinase) phosphorylates IkB (inhibitor
of kB), leading to its dissociation from NF-kB, thereby allowing
NF-kB to enter the nucleus (Sun and Ley, 2008). We found that
compared to LPS-stimulated WT cells, knockdown of VEGFR-
3 increased p-IKKa, p-IKKb, and p-IkBa amounts (Figure 5B).
Importantly, exogenous VEGF-C treatment decreased p-IKKa,
p-IKKb, and p-IkBa amounts in LPS-stimulated WT macro-
phages (Figure 5B).
Next, we assessed how Vegfr3DLBD/DLBD PEMs affected
NF-kB activation after LPS treatment. Compared to the WT or
heterozygous cells, the percentages of p65 nuclear translocation
(Figure 5C), and the p-IKKa and p-IKKb expression (Figure 5D)
were increased in Vegfr3DLBD/DLBD PEMs after LPS stimulation.
Furthermore, compared to RAW264.7 cells expressing GFP con-
trol, the relative amount of p65 in the nuclei was increased
by overexpression of Vegfr3TKmut, but reduced by overexpres-
sion of WT Vegfr3 (Figure S5A). Consistently, LPS-stimulatede measured with or without LPS stimulation in (E) WT PEMs in the absence or
, or (G) PMA-treated human THP-1 cells that overexpressed VEGFR-3 or the
*p% 0.05, **p% 0.01. See also Figure S2. N.C., negative control.
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Figure 3. The VEGFR-3 Ligand-Binding Domain Protects against LPS- or Gram-Negative Bacteria- Induced Septic Shock
The Vegfr3WT/WT, Vegfr3WT/DLBD, or Vegfr3DLBD/DLBD mice were used.
(A and D) BMMs from these mice were treated with or without LPS to examine the production of IL-6, IL-1b, and TNF-a or CCL2, CXCL10.
(B, C, E, and F) These mice were intraperitoneally (i.p.) injected with LPS or intravenously (i.v.) injected with SL1344 to monitor the survival rates and lung injury by
H&E staining (n = 59).
(legend continued on next page)
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Figure 4. The Tyrosine Kinase Activity of
VEGFR-3 Is Critical for Inhibition of Septic
Shock
(A) The survival rates and body weight changes in
the WT and Vegfr3WT/TKmut mice that were i.v. in-
jected with SL1344. Each line represents one
mouse (gray: Vegfr3WT/WT; red: Vegfr3WT/TKmut).
Black solid and red dotted lines represent the
average changes of the WT and Vegfr3WT/TKmut
mice, respectively (n = 8).
(B) H&E staining of lungs from the PBS-treated
control or SL1344-infectedWT and Vegfr3WT/TKmut
mice.
(C and D) Serum IL-6 concentrations, the mRNA
expression of IL-6, IL-1b, TNF-a in livers, or
IL-10 in spleens in SL1344-infected WT and
Vegfr3WT/TKmut mice.
Error bars represent mean ± SEM, representative
of three experiments, *p% 0.05, **p% 0.01. Scale
bars represent 50 mm. See also Figure S4.
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VEGFR-3 Limits TLR4-Triggered Inflammatory ResponseVegfr3WT/TKmut PEMs also increased p-IKKa and p-IKKb expres-
sion compared with the WT controls (Figure S5B). Together, we
demonstrated that VEGFR-3 signaling inhibits TLR4-induced
NF-kB activation.
In addition to TLR4, TLR3 and TLR9 could activate the NF-kB
pathway in response to bacterial infection (Akira and Takeda,
2004). We therefore checked whether Poly(I:C)/TLR3 and CpG/
TLR9 signaling affected VEGFR-3 expression and signaling.
CpG and Poly(I:C) treatment increased VEGFR-3 expression,
which was blocked by the NF-kB inhibitor PDTC (Figure 5E). In
addition, exogenous interferon-b (IFN-b) enhanced VEGFR-3(G and H) BMMs from these mice were stimulated with or without LPS in the presence of the GSK3 inhibitor
mRNA expression or the p-GSK3b amounts.
Error bars represent mean ± SEM, representative of at least two experiments, *p% 0.05, **p% 0.01. Scale
significant.
Immunity 40, 501–5expression that was also inhibited by
PDTC or in MyD88 deficient macro-
phages (Figure S5C). Compared to the
WT or heterozygous cells, CpG-stimu-
lated Vegfr3DLBD/DLBD macrophages
enhanced the mRNA expression of IL-6,
IL-1b, TNF-a, but to a lesser extent than
those treated with LPS (Figure 5F).
Further, knocking down of VEGFR-3
enhanced CpG-triggered IL-6 production
(Figure S5D), suggesting a negative role
of VEGFR-3 in TLR9-induced inflamma-
tory response. By contrast, Poly(I:C)
induced production of these proinflam-
matory cytokines at lower amounts, and
only minor enhancement was occasion-
ally observed in the Vegfr3DLBD/DLBD
macrophages (Figure 5F). In addition,
overexpression of VEGFR-3 in 293T cells
did not affect TRIF-mediated activation
of NF-kB according to the luciferase
assays (Figure S5E). These data suggestthat VEGFR-3 inhibits proinflammatory cytokine production
primarily in LPS-treated macrophages.
VEGFR-3 Binds and Phosphorylates p85a to Activate the
PI3K-Akt1 Pathway
Next, we asked howVEGFR-3 interactedwith other key signaling
components to inhibit the TLR4-NF-kB pathway. Anti-Flag
immunoprecipitation was performed in pervanadate-treated
RAW264.7 cells overexpressing Flag-tagged VEGFR-3. Immu-
noblotting was performed with antibodies against MyD88,
TRAF6, TRIF, TAK1, TBK1, or hemagglutinin (HA)-tagged TIRAP.SB216763 (10 mM) or DMSO to examine the IL-10
bars represent 50 mm. Also see Figure S3. NS, not
14, April 17, 2014 ª2014 Elsevier Inc. 507
Figure 5. VEGFR-3 Suppresses TLR4-Triggered NF-kB Activation
(A) The percentages of p65 in the nucleuswere quantified in the control siRNA or siVEGFR-3 transfected PEMs after LPS treatment. More than 300 cells from each
sample were measured.
(B) The amounts of p-IKKa, p-IKKb, and p-IkBa in the control siRNA or siVEGFR-3 transfected PEMs after LPS stimulation in the presence or absence of VEGF-C.
(C and D) The percentages of p65 in the nucleus or the amounts of p-IKKa and p-IKKbweremeasured in themock or LPS-stimulated BMMs from theVegfr3WT/WT,
Vegfr3WT/DLBD, or Vegfr3DLBD/DLBD mice.
(E) The VEGFR-3 mRNA expression was examined in Poly (I:C)- or CpG-stimulated PEMs, in the presence of DMSO or PDTC.
(F) The mRNA expression of IL-6, IL-1b, and TNF-a in Poly(I:C)- or CpG- stimulated BMMs from the Vegfr3WT/WT, Vegfr3WT/DLBD, or Vegfr3DLBD/DLBD mice.
Bars represent mean ± SEM, representative of three experiments, *p% 0.05, **p% 0.01. Scale bar represents 20 mm. See also Figure S5.
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VEGFR-3 Limits TLR4-Triggered Inflammatory ResponseNone of them demonstrated a physical interaction with VEGFR-3
(Figure S6A). Because the kinase inactive mutant Vegfr3TKmut
considerably reduced its tyrosine phosphorylation (Figure 6A)
and failed to inhibit TLR4 signaling, we asked whether VEGFR-
3 bound negative regulatory molecules that contain SH2
domains. PI3K and Lyn negatively regulate the TLR4-NF-kB
pathway (Aksoy et al., 2012; Guha and Mackman, 2002; Keck
et al., 2010); both contain SH2 domains and translocate proximal
to the cell membrane after LPS stimulation. This location physi-
cally facilitates their association with surface receptors contain-
ing phosphorylated tyrosines.
We found that autophosphorylated VEGFR-3 bound to the
PI3K regulatory subunit p85a (Figure 6BC), but failed to interact
with Lyn (Figure S6B). The four tyrosines (Y1230, 1231, 1337,
1363) in the carboxyl-terminal tail of VEGFR-3 were reported
to be critical for phosphorylation (Dixelius et al., 2003). We
mutated these sites to generate Vegfr34YFmut. To our surprise,
Vegfr34YFmut did not reduce its tyrosine phosphorylation and still
bound p85a (data not shown). By contrast, Vegfr3TKmut greatly
reduced tyrosine phosphorylation (Figure 6A), failed to interact
with HA-tagged p85a, which also diminished the phosphoryla-
tion amounts of p85a (Figure 6B). Notably, overexpression of
VEGFR-3 promoted p85a phosphorylation (Figure 6B). Deletion
of the SH2 domains of p85a (i.e., p85aDSH2) abolished its inter-
action with Flag-tagged VEGFR-3, and vice versa (Figure 6C).
Next, immunoprecipitation with an anti-VEGFR-3 antibody was
performed in untreated or VEGF-C-treated RAW264.7 cells,
followed by blotting with p-p85a. Importantly, VEGF-C-treat-
ment enhanced the interaction between endogenous p85 and
VEGFR-3 (Figure 6D). These findings demonstrate that VEGFR-
3 tyrosine phosphorylation and kinase activity is crucial to recruit
and phosphorylate p85a.
The regulatory subunit p85a forms a heterodimer with the cat-
alytic subunit p110d to assemble class IA PI3K. Occupancy of
the SH2 domains in p85a by phosphotyrosine peptides could
release its inhibitory effect on p110d, resulting in the activation
of PI3K (Burke et al., 2011). In agreement with this, the phosphor-
ylation amounts of PI3K and Akt (Ser473) were substantially
reduced in LPS-stimulated Vegfr3WT/TKmut BMMs (Figure S6C).
Compared with the controls, knockdown of VEGFR-3 also
decreased the p-Akt (Ser473) amounts after LPS treatment (Fig-
ure 6E). Furthermore, exogenous VEGF-C treatment enhanced
LPS-induced p-Akt (Ser473) amounts in the control cells,
whereas this was blocked in VEGFR-3 knockdown cells (Fig-
ure S6D). We next asked whether Akt1 was a major downstream
target of VEGFR-3 to inhibit proinflammatory cytokine produc-
tion. Akt1 deficiency (Figure 6F) or treatment with the Akt inhib-
itor Triciribine (Figure S6E) promoted IL-6 or IL-1b production
in LPS-treated macrophages. Next, the WT, Vegfr3WT/DLBD, or
Vegfr3DLBD/DLBD macrophages were transduced with a consti-
tutively activate form of Akt1 (myristoylated Akt1, termed myr-
Akt1). The excessive amount of p65 nuclear translocation was
rescued by myr-Akt1 in LPS-treated Vegfr3DLBD/DLBD macro-
phages as those in the control samples (Figure 6G).
Independent studies have demonstrated that Akt1 and the cat-
alytic p110d subunit of PI3K affect TLR4 internalization and TLR4
mRNA expression to inhibit NF-kB activation (Aksoy et al., 2012;
Androulidaki et al., 2009). Although we observed com-
parable TLR4 mRNA expression in the WT, Vegfr3WT/DLBD, orVegfr3DLBD/DLBD macrophages (data not shown), LPS-treated
Vegfr3DLBD/DLBD cells indeed internalized surface TLR4 at a
much slower rate as analyzed by flow cytometry (Figure 6H) or
confocal microscopy (Figure S6F). Together, we propose that
the PI3K-Akt1 module is a key downstream component in
VEGFR-3 signaling to enhance TLR4 internalization.
VEGFR-3 Induces SOCS1 Expression to Inhibit
TLR4-NF-kB Signaling
SOCS1 has been characterized as a negative regulator of LPS-
induced inflammation in macrophages (Kinjyo et al., 2002;
Mansell et al., 2006; Nakagawa et al., 2002), and Akt1 deficiency
decreases the induction of SOCS1 (Androulidaki et al., 2009).We
therefore asked whether VEGFR-3 signaling influenced SOCS1
expression. In contrast to the unchanged SOCS3 mRNA
expression, Vegfr3DLBD/DLBD PEMs reduced SOCS1 expression
compared with the WT or Vegfr3WT/DLBD cells after SL1344-
infection (Figure 7A). Exogenous VEGF-C treatment also
increased SOCS1 mRNA expression in macrophages (Fig-
ure 7B). We next asked whether SOCS1 was downstream of
VEGF-C treatment for IL-6 production. Although exogenous
VEGF-C reduced IL-6 production in the control cells, this effect
was significantly diminished in siSOCS1-transfected macro-
phages (Figure 7C). In agreement with this, while VEGF-C
reduced p-IKKa and p-IKKb amounts in LPS-triggered control
sample, this effect was blocked after knockdown of SOCS1 (Fig-
ure 7D). Furthermore, exogenous VEGF-C reduced IL-6 mRNA
expression in LPS-stimulated WT or Vegfr3WT/DLBD cells but
failed to decrease it in the Vegfr3DLBD/DLBD cells. And, knock-
down of SOCS1 enhanced IL-6 production in the WT or
Vegfr3WT/DLBD macrophages, which reached to similar amounts
as those in the Vegfr3DLBD/DLBD macrophages (Figure 7E).
Together, it suggests that VEGFR-3-VEGF-C signaling enhances
SOCS1 expression to inhibit TLR4-NF-kB pathway.
DISCUSSION
Previous studies have documented that elevated VEGF-C could
stimulate VEGFR-3 on lymphatic vessels or macrophages to
promote lymphangiogenesis or skin inflammation resolution (Ali-
talo et al., 2005; Huggenberger et al., 2011; Kataru et al., 2009).
In this study, we provided evidence that serum VEGF-C (but not
VEGF-D) is significantly increased during septic shock, suggest-
ing a new diagnostic biomarker for sepsis in human or animals.
We also identified VEGFR-3 as a cell surface molecule that sup-
presses the TLR4-NF-kB signaling cascade in macrophages.
Unlike various intracellular negative molecules, VEGFR-3 is a
surface receptor and possesses tyrosine kinase activity. This
unique property of VEGFR-3 has been employed for clinical ap-
plications, including usage of anti-VEGFR-3 blocking antibodies
or specific inhibitors to treat tumors (Kirkin et al., 2004; Laakko-
nen et al., 2007). Our study has revealed that TLR4-MyD88-NF-
kB signaling enhanced VEGF-C-VEGFR-3 expression, which in
turn formed a feedback loop to inhibit TLR4-triggered inflamma-
tory responses in macrophages (Figure S7). Triggering VEGFR-3
signaling, for example by VEGF-C ligation, might be applied to
protect the host from severe infections and sepsis.
VEGF-C ligation enhances tyrosine phosphorylation of
VEGFR-3 (Olsson et al., 2006). We showed that VEGFR-3 bindsImmunity 40, 501–514, April 17, 2014 ª2014 Elsevier Inc. 509
(legend on next page)
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Figure 7. VEGFR-3 Induces SOCS1 Expres-
sion to Inhibit TLR4-NF-kB Signaling
(A) The mRNA expression of SOCS1 or SOCS3 in
the mock or LPS-stimulated PEMs from the WT,
Vegfr3WT/DLBD, and Vegfr3DLBD/DLBD mice.
(B) The mRNA expression of SOCS1 in exogenous
VEGF-C-treated PEMs.
(C) The mRNA expression of IL-6 in the control
siRNA or siSOCS1 transfected PEMs which were
stimulated with LPS in the presence or absence of
exogenous VEGF-C.
(D and E) The WT, Vegfr3WT/DLBD, or
Vegfr3DLBD/DLBD macrophages were transfected
with the control siRNA or siSOCS1. After treated
with LPS in the presence or absence of VEGF-C,
the amounts of p-IKKa and p-IKKb or the mRNA
expression of IL-6 was examined.
Error bars represent mean ± SEM, representative
of three experiments, *p% 0.05, **p% 0.01. N.C.,
negative control; NS, not significant.
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VEGFR-3 Limits TLR4-Triggered Inflammatory Responseand phosphorylates p85a, critically depending on its tyrosine ki-
nase activity. The activated VEGFR-3-PI3K-Akt pathway could
then inactivate GSK3b to increase IL-10 production. Similar to
VEGF-C, some other endogenous cytokines have been sug-
gested as negative regulators of TLR4 signaling. For example,
prior exposure ofmacrophages to TNF results in endotoxin toler-
ance (Park et al., 2011). TNF pretreatment diminishes TLR4-trig-
gered inflammation, which is mediated via GSK3 to terminate
NF-kB activation (Park et al., 2011). Another group provided
further evidence that the GSK3 inhibitor SB216763 potently sup-
presses LPS-induced inflammation and protects mice from
E. coli-induced endotoxin shock (Martin et al., 2005). These in-
vestigators proposed that GSK3 could potentially serve as a
therapeutic target for treating sepsis or inflammatory diseasesFigure 6. VEGFR-3 Binds and Phosphorylates p85a to Activate the PI3K-Akt1 Pathway
(A–C) Immunoprecipitation using anti-Flag or anti-HA antibodies was performed in 293T cells transfected w
Flag-tagged Vegfr3 or Vegfr3TKmut and HA-tagged p85a, (C) Flag-tagged Vegfr3 and HA-tagged p85a or
indicated antibodies.
(D) Anti-VEGFR-3 immunoprecipitation was performed using macrophages that were treated with prevenda
followed by immunoblotting with the indicated antibodies.
(E) LPS-induction of the p-Akt (S473) amounts in the control siRNA or siVEGFR-3 transfected macrophages
(F) The mRNA expression of IL-1b and IL-6 in the mock or LPS-stimulated BMMs from the Akt1+/ and Akt1
(G) TheWT, Vegfr3WT/DLBD, and Vegfr3DLBD/DLBDmacrophageswere transfectedwith the empty vector ormy
the percentage of p65 nuclear translocation.
(H) Surface TLR4 expression was examined in the mock or LPS-stimulated WT, Vegfr3WT/DLBD, and Vegfr3D
Error bars represent mean ± SEM (mean ± SD in G), representative of three experiments, *p% 0.05, **p% 0.01
significant.
Immunity 40, 501–5(Martin et al., 2005). Given our findings
that VEGFR-3-VEGF-C activates PI3K-
Akt, which then affects GSK3b phos-
phorylation, it will be important to
further investigate whether treatment
with VEGF-C or in combination with the
GSK3b inhibitor could induce endotoxin
tolerance or prevent severe infections.
Except for the TLR4- andTLR9-induced
expression of VEGFR-3 and its subse-
quent effect on antibacterial responses,we also observed TLR3- or IFN-b-induced VEGFR-3 expression.
IFN-b was reported to activate NF-kB via TRAF2-dependent
pathway (Du et al., 2007), which might explain our data that
PDTC blocked IFN-b-induced VEGFR-3 expression. We also
observed that Myd88 was critical for IFN-b-induced VEGFR-3
expression. This might be because Myd88 directly interacts with
IFNGR1 (IFNg receptor 1) (SunandDing, 2006),which formsahet-
erodimer with IFNGR2, and IFNGR2 is constitutively associated
with IFNAR1 (type I IFN receptor 1) (Takaokaet al., 2000).Because
the Poly(I:C)-TLR3signaling fails to induce IL-6or TNF-a in human
macrophages or dendritic cells (Lundberg et al., 2007) but primar-
ily triggers IFNproduction to clear viral infection, it is interesting to
further study whether VEGFR-3 could crosstalk with TLR3 or IFN
receptors and regulate antiviral responses.ith (A) Flag-tagged Vegfr3 or Vegfr3TKmut alone, (B)
p85aDSH2, followed by immunoblotting with the
date (PVD) in the presence or absence of VEGF-C,
.
/ mice.
r-Akt1, treatedwith LPS followed by examination of
LBD/DLBD PEMs.
. See also Figure S6. N.C., negative control; NS, not
14, April 17, 2014 ª2014 Elsevier Inc. 511
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VEGFR-3 in other immune cells. Our study suggests that
VEGFR-3-VEGF-C signaling regulates PI3K-Akt1 activation
and SOCS1 expression. The PI3K-Akt1 signaling pathway has
been identified as a strong repressor of entry into the CD4+
FoxP3+ regulatory T (Treg) cell phenotype (Haxhinasto et al.,
2008; Sauer et al., 2008), and p110d is essential for Treg cell
suppressive function (Patton et al., 2006). Furthermore, SOCS1
controls Treg cell suppressive ability (Takahashi et al., 2011),
and inhibition of SOCS1 in dendritic cells could break self-toler-
ance and induce antitumor responses (Evel-Kabler et al., 2006).
Therefore, it will be intriguing to examine whether and how
VEGFR-3 signaling affects Treg or dendritic cells.
Previous studies have identified that the inherited Vegfr3
missense mutations (R1041P, L1044P, or P1114L) occur in pri-
mary human lymphoedema patients (Karkkainen et al., 2000)
who are complicated by infections (Karkkainen and Petrova,
2000). The Chy or Vegfr3WT/TKmut mouse model represents a
similar lymphoedema phenotype to human patients (Karkkainen
et al., 2000). Interestingly, we found that these mice were more
sensitive to bacterial infection. Because VEGF-C therapy has
been applied to treat lymphoedema by targeting lymphatic ves-
sels in mousemodels (Tammela et al., 2007), our study proposes
an unrecognized role of VEGF-C therapy for lymphoedema
by targeting the immune system. Furthermore, because we
observed that the Chy mice enhanced sensitivity to endotoxin
shock induction, it would be fundamental to explore whether
human patients with susceptibility to severe infections or sepsis
are associated the identified Vegfr3missense mutations or other
polymorphisms, mutations, or truncations of Vegfr3.
Together, we propose a model in which TLR-triggered
VEGFR-3-VEGF-C expression can dampen TLR4-NF-kB
signaling, which represents a self-control mechanism to prevent
uncontrolled inflammation in macrophages during bacterial
infection. This study not only identifies VEGFR-3-VEGF-C as a
therapeutic target or diagnostic marker for severe infections,
but also extends our understanding that VEGFR-3-VEGF-C
therapy might target both lymphatic vessels and immune cells
for the treatment of lymphoedema.EXPERIMENTAL PROCEDURES
Mice
The 4th6th exons of Vegfr3 gene were flanked by two loxP sites to generate
the mice expressing the truncated Vegfr3DLBD (Zhang et al., 2010). LysM-
Cre-mediated recombination specifically targets genes in the myeloid cell line-
age. The Vegfr3-LBDflox/WT mice were crossbred with Vegfr3WT/DLBD;LysM-
Cre+/+ mice to generate Vegfr3-LBDWT/WT;LysM-Cre+/, Vegfr3-LBDWT/flox;
LysM-Cre+/, Vegfr3-LBDflox/DLBD;LysM-Cre+/ mice, which expressed
Vegfr3WT/WT, Vegfr3WT/DLBD, and Vegfr3DLBD/DLBD specifically in myeloid
cells; these mice were on C57BL6 background. The Vegfr3WT/TKmut (also
named Chy) mice are on the C3H background. The MyD88 KO mice and
Akt1 KOmice (kindly provided by Dr. B. Ge, SIBS, CAS, & Dr. Z. Yang, Nanjing
University, China) are on C57BL6 background. Animal studies were approved
by the institutional animal facility of Shanghai Institutes for Biological Sciences
or National Institute for Viral Disease Control and Prevention.
LPS Shock Models and SL1344 Infection
The age- and sex-matched Vegfr3WT/WT versus Vegfr3WT/TKmut or Vegfr3WT/WT,
Vegfr3WT/DLBD versus Vegfr3DLBD/DLBD mice were injected intraperitoneally
with LPS (35 mg/kg) to induce LPS shock. The S. Typhimurium strain512 Immunity 40, 501–514, April 17, 2014 ª2014 Elsevier Inc.SL1344 (a kind gift from Dr. WH Fang, Zhejiang University, China) was diluted
in 200 ml PBS and injected intomouse tail veins of Vegfr3WT/TKmut mice (53 104
CFU/ml) or Vegfr3DLBD/DLBD mice (5 3 103 CFU/ml). Mice were monitored for
survival rates; serum and target organswere collected at indicated time points.
Preparation of Macrophages
Primary macrophages, 293T, and RAW264.7 cell lines were maintained in
complete DMEM supplemented with 10% (vol/vol) FBS, penicillin, and strep-
tomycin (100 U/ml). Mice were injected peritoneally with 2.5 ml 3%Brewer thi-
oglycollate medium to harvest peritoneal elucidated macrophages (PEMs).
Bone-marrow-derived macrophages (BMMs) were generated after cultured
with L929-conditioned completed DMEM medium for a week. Alternatively,
bone marrow cells were infected with retroviral supernatants expressing
myr-Akt1, selected with puromycin (1.5 mg/ml) containing medium for
2 days, and survival BMMs were used.
Antibodies and Reagents
p-Akt (Ser473), p-PI3Kp85(Tyr458) p55(Tyr199), p-IkBa (Ser32/36), p-IKKa
and p-IKKb (Ser176/Ser180), p-GSK3b (Ser9) were from Cell Signaling Tech-
nology. Anti-p65 was from Santa Cruz Biotechnology. Anti-p85a and anti-
Lyn were from Epitomics. Anti-b-Actin was from Abcam. LPS, anti-Flag, and
anti-HA were from Sigma. Anti-phosphotyrosine antibody (4G10) was from
Millipore. APC-anti-B220, FITC–anti-CD4, FITC-anti-CD3ε, PE-anti-CD8a,
APC-anti-F4/80, FITC-anti-CD11b, anti-TLR4, and anti-VEGFR-3 were from
eBioscience or BD PharMingen. Recombinant murine M-CSF was from R&D
Systems. Protein G beads were from GE healthcare. ELISA kits for IL-1b, IL-
6, TNF-a, VEGF-C, and VEGF-D were from eBioscience or Westang Bio-
tech. PDTC was from Beyotime. Poly(I:C) HMW and type B oligonucleotide
CpG were from InvivoGen. Recombinant human VEGF-C or IFN-b were from
PeproTech.
Plasmids, siRNAs, and qRT-PCR
Flag-tagged murine VEGFR-3 (WT, TKmut, and DLBD) was subcloned into the
retroviral vector pMX-IRES-GFP, and transfected with pCL-10A to 293T cells.
Retroviral supernatants were collected to infect RAW264.7 cells, followed by
sorting GFP+ cells. HA-tagged p85a or p85aDSH2 were subcloned into the
MIGR-IRES-GFP vector. Constitutively active Akt1 (myr-Akt1) in pMSCV was
kindly provided by Dr. G. Wang (SIBCB, CAS). The synthesized siRNAs
(GenePharma) were transfected into macrophages with Lipofectamine 2000.
Total RNA was extracted from cells with Trizol reagent (Sigma). cDNA was
generated with M-MLV transcriptase (Promega) and Random Primer 50-
d(NNN NNN)-30 primers (Sangon). Quantitative RT-PCR was performed on a
CFX-96 machine (Bio-rad) with SYBR Green Master Mix (DBI Bioscience).
Primer or siRNA sequences were in Supplemental Experimental Procedures.
Immunostaining, Immunoprecipitation, ChIP Assay
BMMs or PEMs were stimulated by LPS (1 mg/ml) for different time as indi-
cated, mounted on coverslips, fixed, permeabilized, and then stained with
anti-p65 and Hoechst. Images were taken by Olympus BX-81 or Leica
confocal microscopy. For flow cytometric assays, FACS Calibur, LSR II,
Aria II, Accuri C6 (BD Biosciences), and FlowJo software (Tree Star) were
used. Cotransfected Flag-tagged VEGFR-3 and HA-tagged p85a or HA-Tirap
(kindly provided by Dr. R. Medzhitov, Yale Univeristy) were prepared for immu-
noprecipitation or immunoblotting with indicated antibodies. ChIP assays
were performed with rabbit IgG and anti-p65 antibodies, and the amount of
VEGFR-3 DNA fragments in the immunoprecipitated chromatin was quantified
by RT-PCR.
Statistical Analysis
Kaplan-Meier curves present mouse survival rates; statistical significance
is determined by a two-tailed Student’s t test or a two-way ANOVA with
Graphpad Prism 5.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2014.01.013.
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